高危前列腺癌定义异质性及其对根治性前列腺切除术后死亡率的不同影响
回顾性研究纳入1995至2007年在两家医院接受根治性前列腺切除术的6477例临床局限期前列腺癌患者,评估七种高危定义对死亡率的影响。不同定义下高危患者占比0.7%至8.2%,10年前列腺癌生存估计89.7%至69.7%,总生存58.1%至83.4%。多变量分析中所有高危定义均与更高的前列腺癌特异性死亡风险相关(HR 4.38至19.97,均p<0.001)。
要点
- 不同高危定义下高危患者占比从0.7%(cT3)到8.2%(D'Amico)不等。
- 10年前列腺癌生存估计从89.7%(PSA≥20ng/ml)到69.7%(cT3),总生存58.1%至83.4%。
- 除PSA≥20ng/ml外,所有高危定义均与更高的总死亡风险相关(HR 1.72至3.31,均p<0.01)。
核心结论
- 高危前列腺癌的结局因所采用的治疗前高危定义不同而存在异质性,临床分期T3和Gleason评分8-10与前列腺癌特异性死亡和总死亡的相关性最强。
研究设计与样本
- 回顾性研究纳入1995至2007年在Barnes-Jewish医院(美国圣路易斯)和克利夫兰诊所(美国克利夫兰)接受根治性前列腺切除术的6477例临床局限期前列腺癌患者,中位随访67个月。
主要发现
- 不同高危定义下高危患者占人群比例从0.7%(cT3标准)到8.2%(D'Amico标准)不等。
- 10年前列腺癌生存估计从89.7%(PSA≥20ng/ml)到69.7%(cT3),总生存从83.4%到58.1%。
- 多变量分析中所有高危定义均与更高的前列腺癌特异性死亡风险相关(HR从4.38(PSA≥20ng/ml)到19.97(cT3),均p<0.001)。
- 除术前PSA≥20ng/ml外,所有高危定义均与更高的总死亡风险相关(HR从1.72(D'Amico)到3.31(cT3),均p<0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple definitions of high-risk prostate cancer (PC) exist in clinical practice. Prior studies have primarily evaluated the variability in prediction of biochemical recurrence. OBJECTIVE: To examine the impact of different definitions on mortality after radical prostatectomy (RP). DESIGN, SETTING, AND PARTICIPANTS: Retrospective study of 6477 men with clinically localized disease undergoing RP at Barnes-Jewish Hospital (St. Louis, MO, USA) and Cleveland Clinic (Cleveland, OH, USA) between 1995 and 2007. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Seven pretreatment definitions of high-risk PC (prostate-specific antigen [PSA] ≥20ng/ml, biopsy Gleason score 8-10, clinical stage ≥T2c, cT3, D'Amico definition, National Comprehensive Cancer Network definition, Kattan nomogram) were evaluated. The Kaplan-Meier method was used to generate unadjusted survival estimates. Multivariable Cox proportional hazard regression models (controlling for age) were used to estimate the hazard ratio (HR) for PC-specific mortality (PCSM) and overall mortality (OM) in the high-risk group compared to men with lower risk not meeting that definition. RESULTS AND LIMITATIONS: 6477 men were treated with RP from 1995 to 2007 and were followed for a median of 67 mo. Depending on the definition, patients with high-risk PC comprised between 0.7% (when using cT3 as the criterion) and 8.2% (when using the D'Amico criterion) of the population. The 10-yr PC survival estimates varied from 89.7% (PSA ≥20ng/ml) to 69.7% (cT3) and overall survival ranged from 83.4% to 58.1%. On multivariable analysis, all high-risk definitions were associated with a higher risk of PCSM compared to lower risk (HR ranging from 4.38 for PSA ≥20ng/ml to 19.97 for cT3; all p<0.001). All definitions of high risk except for preoperative PSA ≥20ng/ml were associated with a higher risk of OM (HR 1.72 for D'Amico to 3.31 for cT3; all p<0.01). CONCLUSIONS: Heterogeneity in outcomes existed, depending on the pretreatment definition of high-risk PC. Clinical stage T3 and Gleason score 8-10 were most strongly associated with PCSM and OM. PATIENT SUMMARY: There is variability in prostate cancer outcomes after surgery, depending on the definition of pretreatment high-risk disease used. Clinical stage T3 and high Gleason score were most strongly associated with prostate cancer-specific mortality and overall mortality.
引用
- Mossanen M, Nepple KG, Grubb RL, et al. Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy. Eur Urol Oncol. 2018. PMID: 31100238. doi:10.1016/j.euo.2018.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。